# A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

> **NCT06902545** · — · RECRUITING · sponsor: **Astellas Pharma Korea, Inc.** · enrollment: 377 (estimated)

## Conditions studied

- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
- Metastatic Gastric Adenocarcinoma or Cancer
- Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** zolbetuximab

## Key facts

- **NCT ID:** NCT06902545
- **Lead sponsor:** Astellas Pharma Korea, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2030-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 377 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06902545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06902545, "A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06902545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*